08:24 AM EDT, 06/24/2025 (MT Newswires) -- Nektar Therapeutics ( NKTR ) said Tuesday that the phase 2b study of investigational rezpegaldesleukin met its primary endpoint in patients with moderate to severe atopic dermatitis.

The trial showed a mean improvement in score from baseline at week 16 for all three dose arms of rezpegaldesleukin when compared to placebo, the company said.

All three dose arms also showed statistical significance for key secondary endpoints of disease reduction, the company said.

The safety profile for the 16-week induction period for the treatment was consistent with previously reported results, Nektar said.

Nektar said it plans to submit the findings for presentation at a medical conference later this year.

Top-line data for rezpegaldesleukin in alopecia areata is also expected in Q4, the company said.

Nektar shares were up 141% in recent premarket activity on Tuesday.